The story of Viagra and its originator, copyright, presents a tangled picture for prospective investors. While the blockbuster drug initially fueled enormous revenues , its patent has expired , leading to rival alternatives flooding the arena. This erosion in value presents a substantial hurdle for copyright and any fund considering a heavy positio